The findings – particularly those with respect to haplotype 4, which had the most substantial impact – could play a role in patient risk assessment.
“Potentially, although it is a relatively uncommon haplotype, pretransplant identification of haplotype 4 may well have implications for transplant decision making, given the fact that the majority of our patients with this haplotype did not survive posttransplant,” he concluded, noting that an effort to validate the findings is ongoing in an additional 300 patients.
Dr. Ritchie reported having no financial disclosures.
SOURCE: Koldej R et al. The 2018 BMT Tandem Meetings, Abstract 22.